Immunovant Stock Alpha and Beta Analysis

IMVT -  USA Stock  

USD 8.53  0.28  3.18%

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immunovant. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immunovant over a specified time horizon. Remember, high Immunovant's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Please see Immunovant Backtesting, Immunovant Valuation, Immunovant Correlation, Immunovant Hype Analysis, Immunovant Volatility, Immunovant History and analyze Immunovant Performance.

Immunovant Beta 

 
Refresh
Please note that although Immunovant alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, Immunovant did 0.12  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Immunovant stock's relative risk over its benchmark. Immunovant has a beta of 0.61  . Let's try to break down what Immunovant's beta means in this case. As returns on the market increase, Immunovant returns are expected to increase less than the market. However, during the bear market, the loss on holding Immunovant will be expected to be smaller as well.
Immunovant Price to Book Value is comparatively stable at the moment as compared to the past year. Immunovant reported Price to Book Value of 4.01 in 2020. Enterprise Value is likely to gain to about 1.2 B in 2021, whereas Enterprise Value over EBITDA is likely to drop (11.65)  in 2021.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

Immunovant Quarterly Book Value per Share

3.731Share

Immunovant Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immunovant market risk premium is the additional return an investor will receive from holding Immunovant long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immunovant. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immunovant's performance over market.
α-0.12   β0.61
90 days against DJI

Immunovant expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immunovant's Buy-and-hold return. Our buy-and-hold chart shows how Immunovant performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Immunovant Market Price Analysis

Market price analysis indicators help investors to evaluate how Immunovant stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immunovant shares will generate the highest return on investment. By understating and applying Immunovant stock market price indicators, traders can identify Immunovant position entry and exit signals to maximize returns.

Immunovant Return and Market Media

The median price of Immunovant for the period between Fri, Jul 23, 2021 and Thu, Oct 21, 2021 is 8.72 with a coefficient of variation of 9.21. The daily time series for the period is distributed with a sample standard deviation of 0.8, arithmetic mean of 8.74, and mean deviation of 0.58. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
      Timeline 
1
Unclassified Event08/02/2021
2
Acquisition by Salzmann Peter of 570613 shares of Immunovant...08/04/2021
3
EPS Reported08/09/2021
4
Purchase by Fromkin Andrew J of 5500 shares of Immunovant08/11/2021
5
Purchase by Pande Atul of 5000 shares of Immunovant08/16/2021
6
Immunovant falls 1.15 percent for August 18 - Equities.com08/18/2021
7
Purchase by Migausky George V of 7000 shares of Immunovant08/20/2021
8
Immunovant falls 1.66 percent for August 26 - Equities.com08/26/2021
9
Purchase by Hughes Douglas J of 18247 shares of Immunovant08/30/2021
10
Immunovant gains 4.99 percent in Light Trading on September ...09/02/2021
11
Immunovant falls 3.80 percent in Light Trading on September ...09/10/2021
12
Disposition of 464700 shares by Salzmann Peter of Immunovant...09/14/2021
13
Financial Statements09/15/2021
14
Disposition of 369320 shares by Macias William L of Immunova...09/16/2021
15
Financial Statements09/27/2021
16
Immunovant falls 1.47 percent in Light Trading on September ...09/30/2021
17
Acquisition by Barnett Eva Renee of 59500 shares of Immunova...10/05/2021
18
Acquisition by Jain Rita of 109365 shares of Immunovant subj...10/06/2021
19
Acquisition by Macias William L of 369320 shares of Immunova...10/07/2021
20
Acquisition by Barnett Eva Renee of 333000 shares of Immunov...10/18/2021

About Immunovant Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all equity instruments such as Ford or other stocks, funds, and ETFs. Alpha measures the amount that position in Immunovant has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2010 2019 2020 2021 (projected)
Current Ratio1.947.1221.7917.42
Book Value per Share0.332.184.463.69

Immunovant Upcoming Company Events

As portrayed in its financial statements, the presentation of Immunovant's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunovant's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immunovant's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immunovant. Please utilize our Beneish M Score to check the likelihood of Immunovant's management manipulating its earnings.
Upcoming Quarterly Report11th of November 2021
Next Earnings Report15th of February 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End7th of June 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

Build Portfolio with Immunovant

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunovant Backtesting, Immunovant Valuation, Immunovant Correlation, Immunovant Hype Analysis, Immunovant Volatility, Immunovant History and analyze Immunovant Performance. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Immunovant technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Immunovant technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Immunovant trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...